Neurox ampoules 0.05/ml 5ml n5

Antioxidant drug

Release form

Solution for in / in and in / m the introduction of clear, colorless or slightly yellow.

Excipients: sodium disulfite, water d / and.

2 ml - dark glass ampoules (5) - contoured cell packs (1) - cardboard packs.2 ml - dark glass ampoules (5) - contour cell packs (2) - cardboard packs.2 ml - dark glass ampoules (5) - cell blister packs (4) - packs of cardboard. 2 ml - dark glass ampoules (5) - blister packs (10) - cardboard packs.

Solution for in / in and in / m the introduction of clear, colorless or slightly yellow.

Excipients: sodium disulfite, water d / and.

5 ml - dark glass ampoules (5) - contoured cell packs (1) - cardboard packs.5 ml - dark glass ampoules (5) - contour cell packs (2) - cardboard packs.5 ml - dark glass ampoules (5) - contour cell packages (4) - cardboard packs.

Solution for in / in and in / m the introduction of clear, colorless or slightly yellow.

Excipients: sodium disulfite, water d / and.

10 ml - dark glass ampoules (1) - contoured cell packs (1) - cardboard packs.

Solution for in / in and in / m the introduction of clear, colorless or slightly yellow.

Excipients: sodium disulfite, water d / and.

20 ml - dark glass ampoules (1) - contoured cell packs (1) - cardboard packs.

Mechanism of action

Antioxidant drug. Ethyl methyl hydroxypyridine succinate (EMHPS) is an inhibitor of free radical processes, a membrane protector with antihypoxic, stress protective, nootropic, anticonvulsant and anxiolytic action. Belongs to the class of 3-hydroxypyridines. The mechanism of action is due to antioxidant and membrane-protective properties. Suppresses lipid peroxidation, increases the activity of superoxidase, improves the ratio of lipid-protein, improves the structure and function of the cell membrane. Modulates the activity of membrane-bound enzymes, receptor complexes, which contributes to their binding to ligands, preserving the structural and functional organization of biomembranes, transport of neurotransmitters and improving synaptic transmission. Increases the concentration of dopamine in the brain. It enhances the compensatory activation of aerobic glycolysis and reduces the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in adenosine triphosphoric acid and creatine phosphate, activates the energy-synthesizing function of mitochondria. Increases the body's resistance to the effects of various damaging factors in pathological conditions (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication with ethanol and antipsychotic drugs).It improves the metabolism and blood supply of the brain, microcirculation and rheological properties of the blood, reduces platelet aggregation. Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and LDL. Normalizes metabolic processes in ischemic myocardium, reduces the area of ​​necrosis, restores and / or improves electrical activity and myocardial contractility, and also increases coronary blood flow in the ischemic area, increases the antianginal activity of nitrodrugs, reduces the effects of reperfusion syndrome in acute coronary insufficiency.

The stress-protective effect is manifested in the normalization of post-stress behavior, somatic vegetative disturbances, restoration of sleep-wake cycles, impaired learning and memory processes, reduction of dystrophic changes in various brain structures.

EMHPS has a pronounced anti-toxic effect in abstinence syndrome, eliminates the neurological and neurotoxic manifestations of acute alcohol intoxication, corrects behavioral and cognitive impairment. Under the influence of ethylmethylhydroxypyridine succinate, the effect of tranquilizing, neuroleptic, antidepressive, hypnotic, and anticonvulsant drugs is enhanced, which allows to reduce their doses and reduce side effects.

Pharmacokinetics

For intramuscular administration, the drug is determined in the blood plasma for 4 hours after administration. The time to reach the maximum concentration for intramuscular injection is -0.3-0.58 h. The maximum concentration for intramuscular injection at a dose of 400-500 mg is 2.5-4 μg / ml. Ethyl methyl hydroxypyridine succinate rapidly passes from the bloodstream to organs and tissues and is rapidly eliminated from the body. The average retention time of the drug in the body after intramuscular injection is 0.7-1.3 hours. It is metabolized in the liver by glucuronidation. It is rapidly excreted in the urine mainly as metabolites (50% in 12 hours) and in small quantities in unchanged form (0.3% in 12 hours). Most intensively displayed during the first 4 hours after taking the drug. Indicators of urine excretion of unchanged drug and metabolites have significant individual variability.

Indications for use of the drug

- acute disorders of cerebral circulation (as part of complex therapy);

- encephalopathy;

- cardiopsychoneurosis;

- slight cognitive disorders of atherosclerotic genesis;

- anxiety states in neurotic and neurosis-like states;

- abstinence syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

- acute intoxication with antipsychotic drugs.

>

Dosage and administration

The drug is administered in / m or / in (jet or drip).When the infusion method of administration of the drug should be diluted in a 0.9% solution of sodium chloride.

Doses are selected individually. The initial dose is 50-100 mg 1-3, which is gradually increased to obtain a therapeutic effect.

Jet Neurox is injected slowly over 5-7 minutes, drip - at a speed of 40-60 drops / min.

The maximum daily dose should not exceed 800 mg.

For acute disorders of cerebral circulation, Neurox is used as part of complex therapy for the first 2-4 days in / in a drip of 200-300 mg 1 time /, then in / a 100 mg 3 The duration of treatment is 10-14 days.

When dyscirculatory encephalopathy in the phase of decompensation - in / in the jet or drip in a dose of 100 mg 2-3 for 14 days, then - in / m 100 mg / for the next 14 days.

For course prophylaxis of dyscirculatory encephalopathy, i / m at a dose of 100 mg 2 for 10-14 days.

In case of neurocirculatory dystonia, neurotic and neurosis-like states - intramuscularly by 50-400 mg / for 14 days.

In case of withdrawal syndrome, a / m dose of 100–200 mg 2–3 or intravenous drip 1–2 for 5–7 days.

With acute intoxication with antipsychotic drugs - in / in a dose of 50-300 mg / for 7-14 days.

In cases of mild cognitive impairment in elderly patients and in anxiety disorders, i / m at a dose of 100-300 mg / for 14-30 days.

Side effects

When administered parenterally (especially in / in the jet): dry and "metallic" taste in the mouth, a feeling of "overflowing heat" throughout the body, tickling in the throat and discomfort in the chest, feeling of lack of air (usually associated with excessively high speed introduction and are short-term).

With prolonged use: nausea, flatulence, sleep disturbances (drowsiness or sleep disturbance).

Allergic reactions are possible.

Contraindications

- acute renal failure ;

- acute liver failure;

- pregnancy;

- lactation period;

- childhood;

- increased individual sensitivity to the drug or its components.

Precautions should be prescribed the drug for allergic diseases and reactions in history.

special instructions

Influence on ability to drive motor transport and control mechanisms

During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and psychomotor reactions.

Overdose

Symptoms: sleep disturbances (insomnia, in some cases - drowsiness); with a / in the introduction - a slight and short-term (up to 1.5-2 h) increase in blood pressure.

Treatment: As a rule, the symptoms disappear on their own within 24 hours. In severe cases of insomnia, nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg; with an excessive increase in blood pressure - antihypertensive drugs under the control of blood pressure.

Drug interaction

Enhances the action of benzodiazepine anxiolytics, antiepileptic (carbamazepine), antiparkinsonian (levodopa) drugs, nitrates.

Reduces the toxic effects of ethanol.

Pharmacy sales terms

Dispensing without a doctor's prescription.

Terms and conditions of storage

List B. The drug should be stored in a dry, dark place, out of reach of children at a temperature not exceeding 25 ° C.